Description
Belizatinib, also known as TSR-011, is an oral inhibitor of ALK and TRK.
Description
Belizatinib is an inhibitor of anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases A/B/C (IC
50s = 0.7 and <3 nM, respectively).
Uses
Belizatinib is used in treating diseases via targeted modulation of gene signaling networks.
in vivo
Belizatinib (TSR-011) exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models[1].
References
[1] H. ARKENAU. Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.[J]. Journal of Clinical Oncology, 2015, 33 1: 8063-8063. DOI:
10.1200/jco.2015.33.15_suppl.8063